Relevance of Weight Loss, Splenomegaly, and Hypocholesterolemia in the Treatment of Myeloproliferative Neoplasms— Implications for a JAK2 Inhibitor Era

Oncology & Hematology Review (US)
doi 10.17925/ohr.2011.07.1.61
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Touch Medical Media, Ltd.

Related search

An Exciting New Era in the Treatment of Myeloproliferative Neoplasms

Oncology & Hematology Review (US)
2016English

JAK2 and MPL Mutations in Myeloproliferative Neoplasms: Discovery and Science

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2008English

JAK2 Haplotype Is a Major Risk Factor for the Development of Myeloproliferative Neoplasms

Nature Genetics
Genetics
2009English

JAK2 Exon 14 Deletion in Patients With Chronic Myeloproliferative Neoplasms

PLoS ONE
Multidisciplinary
2010English

The Role of the JAK2 GGCC Haplotype and the TET2 Gene in Familial Myeloproliferative Neoplasms

Haematologica
Hematology
2010English

JAK2, CALR, and MPL Mutation Spectrum in Japanese Patients With Myeloproliferative Neoplasms

Haematologica
Hematology
2014English

Characterization of CD34+ Hematopoietic Progenitor Cells in JAK2 V617F and CALR -Mutated Myeloproliferative Neoplasms

Leukemia Research
Cancer ResearchOncologyHematology
2016English

Classification of Myeloproliferative Disorders in the JAK2 Era: Is There a Role for Red Cell Mass?

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2007English

Role of Mesenchymal Stromal Cells and Their Extracellular Vesicles microRNAs in JAK2 Myeloproliferative Neoplasms

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy